Literature DB >> 30107636

Anhedonia and suicidal thoughts and behaviors in psychiatric outpatients: The role of acuity.

Mariah Hawes1, Igor Galynker1, Shira Barzilay1, Zimri S Yaseen1.   

Abstract

BACKGROUND: Anhedonia-impairment related to the experience of pleasure-has been identified as a potential risk factor for suicide, with some mixed findings. The current study sought to clarify the role of acuity of anhedonia in the relationship between anhedonia and suicidal thoughts and behaviors by comparing acutely and chronically anhedonic subjects on severity of suicidal ideation (SI) and suicide attempt (SA) history.
METHODS: Psychiatric outpatients (N = 395) were administered the Columbia Suicide Severity Rating Scale, the Beck Scale for Suicidal Ideation and a modified version of the Snaith-Hamilton Pleasure Scale (SHPS); SI measures were readministered at a 1-month follow-up (N = 289, 73%). Participants were classified as acutely anhedonic, chronically anhedonic and nonanhedonic based on their responses to the SHPS at initial assessment.
RESULTS: Controlling for symptoms of anxiety and depression, acute anhedonia was cross-sectionally and prospectively associated with greater severity of SI compared to the nonanhedonic group; no differences in severity of SI were found between the chronically anhedonic and nonanhedonic group at either time point. Anhedonia grouping was not associated with SA history.
CONCLUSION: Changes in capacity to experience pleasure may be more informative of near-term SI than typically low pleasure levels. Future investigation should focus on the relationship between acute anhedonia and imminent suicidal behavior.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  assessment/diagnosis; depression; dysthymic disorder; measurement/psychometrics; suicide/self-harm

Mesh:

Year:  2018        PMID: 30107636     DOI: 10.1002/da.22814

Source DB:  PubMed          Journal:  Depress Anxiety        ISSN: 1091-4269            Impact factor:   6.505


  7 in total

1.  Neurocognitive predictors of self-reported reward responsivity and approach motivation in depression: A data-driven approach.

Authors:  Kean J Hsu; Mary E McNamara; Jason Shumake; Rochelle A Stewart; Jocelyn Labrada; Alexandra Alario; Guadalupe D S Gonzalez; David M Schnyer; Christopher G Beevers
Journal:  Depress Anxiety       Date:  2020-06-24       Impact factor: 6.505

Review 2.  Anhedonia and Suicide.

Authors:  Randy P Auerbach; David Pagliaccio; Jaclyn S Kirshenbaum
Journal:  Curr Top Behav Neurosci       Date:  2022

3.  Diminished reward responsiveness is associated with lower reward network GluCEST: an ultra-high field glutamate imaging study.

Authors:  Valerie J Sydnor; Bart Larsen; Christian Kohler; Andrew J D Crow; Sage L Rush; Monica E Calkins; Ruben C Gur; Raquel E Gur; Kosha Ruparel; Joseph W Kable; Jami F Young; Sanjeev Chawla; Mark A Elliott; Russell T Shinohara; Ravi Prakash Reddy Nanga; Ravinder Reddy; Daniel H Wolf; Theodore D Satterthwaite; David R Roalf
Journal:  Mol Psychiatry       Date:  2021-01-21       Impact factor: 13.437

4.  Suicidal ideations among medical students: The role of anhedonia and type D personality.

Authors:  Gwenolé Loas; Alice Solibieda; Marianne Rotsaert; Yvon Englert
Journal:  PLoS One       Date:  2019-06-21       Impact factor: 3.240

Review 5.  Can Anhedonia Be Considered a Suicide Risk Factor? A Review of the Literature.

Authors:  Luca Bonanni; Flavia Gualtieri; David Lester; Giulia Falcone; Adele Nardella; Andrea Fiorillo; Maurizio Pompili
Journal:  Medicina (Kaunas)       Date:  2019-08-09       Impact factor: 2.430

6.  Patient-reported outcomes in major depressive disorder with suicidal ideation: a real-world data analysis using PatientsLikeMe platform.

Authors:  Stephane Borentain; Abigail I Nash; Rachna Dayal; Allitia DiBernardo
Journal:  BMC Psychiatry       Date:  2020-07-23       Impact factor: 4.144

Review 7.  Candidate Biomarkers of Suicide Crisis Syndrome: What to Test Next? A Concept Paper.

Authors:  Raffaella Calati; Charles B Nemeroff; Jorge Lopez-Castroman; Lisa J Cohen; Igor Galynker
Journal:  Int J Neuropsychopharmacol       Date:  2020-04-21       Impact factor: 5.176

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.